A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease
Authors
Keywords
Surgical and invasive medical procedures, Cost-effectiveness analysis, Corticosteroid therapy, Colectomy, Health economics, Ulcerative colitis, Economic agents, Inflammatory bowel disease
Journal
PLoS One
Volume 12, Issue 10, Pages e0185500
Publisher
Public Library of Science (PLoS)
Online
2017-10-04
DOI
10.1371/journal.pone.0185500
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Crohn's disease
- (2017) Joana Torres et al. LANCET
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
- (2016) Ewa Stawowczyk et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model
- (2016) Rachel Archer et al. HEALTH TECHNOLOGY ASSESSMENT
- Biosimilars in IBD: from theory to practice
- (2016) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2016) Rachid Rafia et al. PHARMACOECONOMICS
- A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
- (2016) Paul Tappenden et al. PHARMACOECONOMICS
- Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland
- (2016) Ewa Stawowczyk et al. PHARMACOTHERAPY
- Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
- (2016) Candace L. Beilman et al. Canadian Journal of Gastroenterology and Hepatology
- Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
- (2016) Ewa Stawowczyk et al. PLoS One
- Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn’s Colitis
- (2015) Sasha Taleban et al. DIGESTIVE DISEASES AND SCIENCES
- The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn’s Disease Patients with Adalimumab Non-response in the USA
- (2015) Daniel O. Erim et al. Journal of Crohns & Colitis
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- The global burden of IBD: from 2015 to 2025
- (2015) Gilaad G. Kaplan Nature Reviews Gastroenterology & Hepatology
- Optimizing the use of biological therapy in patients with inflammatory bowel disease
- (2015) A. C. Moss Gastroenterology Report
- Thresholds for the cost–effectiveness of interventions: alternative approaches
- (2015) Elliot Marseille et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases
- (2015) Saara Huoponen et al. PLoS One
- CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
- (2014) Karl Claxton et al. HEALTH ECONOMICS
- Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
- (2014) Aurelien Amiot et al. Therapeutic Advances in Gastroenterology
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease
- (2013) Derek H. Tang et al. INFLAMMATORY BOWEL DISEASES
- The burden of inflammatory bowel disease in Europe
- (2013) Johan Burisch et al. Journal of Crohns & Colitis
- Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing
- (2013) Mark P. Connolly et al. Journal of Crohns & Colitis
- Cost-Effectiveness of Early Colectomy With Ileal Pouch-Anal Anastamosis Versus Standard Medical Therapy in Severe Ulcerative Colitis
- (2012) K. T. Park et al. ANNALS OF SURGERY
- Cost Utility of Inflammation-Targeted Therapy for Patients With Ulcerative Colitis
- (2012) Sameer D. Saini et al. Clinical Gastroenterology and Hepatology
- The Economic Burden of Inflammatory Bowel Disease: Clear Problem, Unclear Solution
- (2012) Christian D. Stone DIGESTIVE DISEASES AND SCIENCES
- Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis
- (2012) Shota Saito et al. Journal of Crohns & Colitis
- Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease
- (2012) Derek H. Tang et al. PHARMACOTHERAPY
- Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis
- (2011) Ashwin N Ananthakrishnan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
- (2011) Anne Prenzler et al. BMC HEALTH SERVICES RESEARCH
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohnʼs disease
- (2011) Glen A. Doherty et al. INFLAMMATORY BOWEL DISEASES
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease
- (2011) Gord Blackhouse et al. Journal of Crohns & Colitis
- Cost Effectiveness of Treatments for Inflammatory Bowel Disease
- (2011) Keith Bodger PHARMACOECONOMICS
- Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adults
- (2010) J. LINDSAY et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective
- (2010) Nic Brereton et al. JOURNAL OF MEDICAL ECONOMICS
- Review: Optimal use of biologics in the management of Crohn’s disease
- (2010) Remo Panaccione et al. Therapeutic Advances in Gastroenterology
- Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data
- (2009) K. BODGER et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease
- (2009) Edward V. Loftus et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Systematic reviews of economic evaluations: utility or futility?
- (2009) Rob Anderson HEALTH ECONOMICS
- An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial
- (2009) Mark P. Connolly et al. Journal of Crohns & Colitis
- A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis
- (2009) Chris D. Poole et al. Journal of Crohns & Colitis
- Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohnʼs Disease
- (2009) Andrew P. Yu et al. PHARMACOECONOMICS
- Utilities of the EQ-5D
- (2009) Saskia Knies et al. PHARMACOECONOMICS
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- The cost effectiveness and budget impact of natalizumab for formulary inclusion
- (2009) Justin Bakhshai et al. JOURNAL OF MEDICAL ECONOMICS
- The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis
- (2008) A. BUCKLAND et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cost-Effectiveness of 5-Aminosalicylic Acid Therapy for Maintenance of Remission in Ulcerative Colitis
- (2008) Eugene F. Yen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial
- (2008) Mark P. Connolly et al. Journal of Crohns & Colitis
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started